Finance
Pharma and Biotech: Strategic, M&A, and Financial Trends 2013
Young & Partners’ "Pharma and Biotech Strategic, M&A, and Financial Trends Report" covers the first three quarters of 2013 and the outlook for 2014. Here, Peter Young highlights the external factors that have had an enormous incremental effect on the trends in pharma and biotech this year and that will continue to have an impact going forward ...Read more
Emerging Markets
Russian Innovation: A Higher Mark
The pursuit of excellence in biopharmaceutical innovation in Russia has never had a sponsor—until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an awards dinner to recognize the best in new drug research as well as innovation in biotechnology and pharmaceutical products ...Read more
Video
Lilly Strategy: Timely, Valued Medicines to Patients
Dr Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline ...View here
Engage your physician/HCP or health consumer audience no matter what they’re up to
At eHealthcare Solutions, we strike the perfect balance of innovation, digital engagement, and reach. For great digital solutions from a different angle, call Rob Carmignani at (609) 882-8887 ext. 100 or visit  www.ehealthcaresolutions.com
Regulatory
Provider Demand to Drive Compound Registration with FDA
The Food and Drug Administration is moving fast to implement the drug compounding provisions of new Drug Quality and Security Act (DQSA), issuing new guidance to spur registration by outsourcing facilities just days after President Obama signed the new bill into law. But implementation will rely largely on market pressures to encourage health care providers to purchase compounded products only from registered facilities ...Read more
Human Error Professional Training – new for 2014
If you think human error is the real cause of your quality problems then think again! Join NSF Health Sciences Pharma Biotech on Tuesday 4 February 2014 for a 2 day training class which uncovers the psychology of human error. Leave us with practical tools and techniques to help reduce so-called ‘human error’ Learn more.
Global
Pharm Exec Global Digest — Personalized Medicine Special
Personalized medicines: Are they worth it?; Pathology in the era of personalized medicine; Clinical trial data disclosure — has Europe bitten off more than it can chew?; China: recruiting amid the corruption fallout; And more! ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
|
